After the FDA adopted a more positive stance towards uniQure's (QURE) gene therapy for Huntington's Disease, AMT-130, the agency is likely to approve the biologic treatment. As a result, QURE stock is dramatically undervalued compared with its long-term potential. However, it still poses a significant risk, making it a buy for long-term growth investors with a meaningful tolerance for risk.